Sökning: onr:"swepub:oai:DiVA.org:hj-62577" >
Open innovation :
Open innovation :
-
- Lo Nigro, Giovanna (författare)
- Dept. of Chemical, Management, Mechanical Engineering and Computer Science, University of Palermo, Italy
-
- Morreale, Azzurra (författare)
- Dept. of Chemical, Management, Mechanical Engineering and Computer Science, University of Palermo, Italy
-
- Enea, Gianluca (författare)
- Ernst and Young - Financial and Business Advisors S.p.a, Milan, Italy
-
Dept of Chemical, Management, Mechanical Engineering and Computer Science, University of Palermo, Italy Ernst and Young - Financial and Business Advisors S.p.a, Milan, Italy (creator_code:org_t)
- Elsevier BV, 2014
- 2014
- Engelska.
-
Ingår i: International Journal of Production Economics. - : Elsevier BV. - 0925-5273 .- 1873-7579. ; 149, s. 183-193
- Relaterad länk:
-
https://iris.unipa.i...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The pharmaceutical landscape has changed, and new business models, based on alliances, are increasingly being adopted in this industry. Biotechnology advances have pushed this development, and pooling complementary resources coming from incumbents and newcomers is a key skill to succeed: these are the premises for a quick spread of the open innovation (OI) paradigm in this industry. R&D portfolio selection needs R&D project evaluation, and Real Options Analysis (ROA) is acknowledged as a powerful tool to evaluate uncertain projects that have an intrinsic flexibility. The present research aims to foster the use of ROA in the OI field in order to encourage firms to undertake this innovation model; to achieve this goal the authors propose a closed-form model that is easy to implement, to evaluate the OI initiative for selecting an optimal R&D portfolio. The study wants to support managers in optimal R&D portfolio construction in terms of choosing the most promising products, the means by which the related project has to be undertaken (in an open or closed manner; i.e. licensing-in or not) and the self-financing policy. The proposed model can be easily implemented into a spreadsheet, and the inputs needed to run it are usually requested to evaluate projects using the most used net-present-value-based methods. Moreover, some parameters of the model allow strategic aspects to be considered: for example the nature of the project (core/non-core), the impending project phase, and the risk-sharing opportunity. The results of the developed numerical example show that the selected portfolio is well balanced in terms of development stages, core/non-core therapeutic areas and, licensing-in (an inbound open innovation solution), is preferred in the case of products at their early stages of development.
Ämnesord
- SAMHÄLLSVETENSKAP -- Ekonomi och näringsliv -- Nationalekonomi (hsv//swe)
- SOCIAL SCIENCES -- Economics and Business -- Economics (hsv//eng)
Nyckelord
- Biopharmaceutical industry
- Licensing
- Open innovation
- R&D portfolio
- Real options analysis
- Closed-form modeling
- Development stages
- New business models
- Portfolio selection
- Project evaluation
- Industry
- Innovation
- Nuclear reactor licensing
- Optimization
- Value engineering
- Project management
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas